Calamos Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

Calamos Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$788K	Buy	+8,535	New	+$803K	﹤0.01%	827
2025 Q4	–	Sell	-43,250	Closed	-$3.17M	–	975
2025 Q3	$3.17M	Buy	43,250 +9,985	+30%	+$635K	0.01%	593
2025 Q2	$1.69M	Sell	33,265 -3,389	-9%	-$151K	0.01%	648
2025 Q1	$1.65M	Buy	+36,654	New	+$1.73M	0.01%	608
2022 Q4	–	Sell	-108,653	Closed	-$2.28M	–	1291
2022 Q3	$2.28M	Buy	108,653 +66,132	+156%	+$1.59M	0.01%	850
2022 Q2	$828K	Buy	+42,521	New	+$1M	﹤0.01%	1039

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Calamos Advisors's MIRM Position: Q1 2026 in Review

Calamos Advisors opened a new position in Mirum Pharmaceuticals (MIRM) in Q1 2026: 8,535 shares worth $788K. The stake represents ﹤0.01% of the portfolio and ranks #827 among its holdings. This is a return to the name: Calamos Advisors previously reported a position in MIRM as recently as Q3 2025.

Calamos Advisors first reported a position in MIRM in Q2 2022 and has held it in 6 quarters since. The position peaked at $3.17M in Q3 2025. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

Calamos Advisors held 8,535 shares of Mirum Pharmaceuticals worth $788K as of Q1 2026.
Mirum Pharmaceuticals was a new Calamos Advisors position in Q1 2026.
Mirum Pharmaceuticals made up ﹤0.01% of Calamos Advisors's portfolio in Q1 2026, its #827 holding.
Calamos Advisors first reported a position in Mirum Pharmaceuticals in Q2 2022 and has held it in 6 quarters since.
Calamos Advisors's Mirum Pharmaceuticals position peaked at $3.17M in Q3 2025.
311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.